Raffles Medical Group (BSL) AI Stock Analysis

• Market Cap: $1.83B
• Dividend Yield: 2.58%
• Average Volume (3M): 1.69M
• Price to Earnings (P/E): 29.0
• Beta (1Y): 0.48
• Revenue Growth: 6.30%
• EPS Growth: -30.93%
• Country: SG
• Employees: 2,989
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Care Facilities
• EPS (TTM): 0.03
• Shares Outstanding: 1,884,544,900
• 10 Day Avg. Volume: 1,070,250
• 30 Day Avg. Volume: 1,693,603
• PEG Ratio: 0.25
• Price to Book (P/B): 2.56
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 15.21
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $1.08
• Price Target Upside: 13.02% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 0

• Rating: 58 Neutral
• Price Target: S$1.00 ▲(4.17%Upside)

Raffles Medical Group's overall stock score is primarily influenced by a strong financial foundation, although challenges in profitability and cash flow generation are concerns. Technical indicators suggest bearish momentum, and the stock's valuation appears high relative to the industry. The absence of earnings call and corporate events data means these factors did not affect the score.

Raffles Medical Group Business Overview & Revenue Model

Company Description

Raffles Medical Group Ltd provides integrated private healthcare services primarily in Singapore, Greater China, Vietnam, Cambodia, and Japan. The company operates through Healthcare Services, Hospital Services, and Investment Holdings segments. Its flagship hospital is the Raffles Hospital, a tertiary care hospital that offers cancer, children and women care, Chinese medicine, counselling, dental, dialysis, diabetes and endocrinology, ear, nose, throat, eye, fertility, heart, internal medicine, neuroscience, pain management, rehabilitation, orthopedic, skin and aesthetics, surgery, nuclear medicine, and urology services. The company also offers emergency services, family medicine services, health screening, and various multi-disciplinary specialist clinic services. In addition, it trades in pharmaceutical and nutraceutical products, and diagnostic equipment; provides advisory and consultancy services, and develops IT solutions; and engages in research and experimental development on biotechnology, and life and medical science. Raffles Medical Group Ltd was founded in 1976 and is based in Singapore.

How the Company Makes Money

Raffles Medical Group generates revenue through multiple streams, primarily from its healthcare services, which include hospital and clinic operations. The company earns income from patient consultations, diagnostic tests, surgical procedures, and inpatient and outpatient care. Additionally, Raffles Medical Group benefits from partnerships with corporate clients, offering employee health and wellness programs. The company also engages in health insurance services, providing a source of income through premiums and policy management. Strategic collaborations and affiliations with international healthcare institutions further enhance its service offerings and revenue potential.

Raffles Medical Group Financial Statement Overview

Summary

Raffles Medical Group exhibits robust revenue growth and a stable balance sheet with low leverage and strong equity. However, declining profit margins and cash flow trends pose challenges to sustaining financial health.

Income Statement

Raffles Medical Group has shown consistent revenue growth over the years, with a notable increase from 2019 to 2024. The gross profit margin has been strong, indicating efficient cost management, but there is a declining trend in both EBIT and net profit margins over the recent years, which might suggest increasing operational costs or competitive pressures affecting profitability.

Balance Sheet

The company maintains a solid equity base relative to its assets, which is reflected in a healthy equity ratio. The debt-to-equity ratio is low, indicating conservative leverage. However, there has been a decrease in net income, which impacts the return on equity negatively. Overall, the balance sheet remains stable with strong liquidity.

Cash Flow

Operating cash flow remains positive, although it has decreased significantly from 2023 to 2024. Free cash flow has also declined in recent years, which could affect future growth investments. The free cash flow to net income ratio indicates a decent conversion of earnings into cash, but the declining trend raises concerns about cash generation sustainability.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
702.87M	751.56M	708.03M	766.54M	723.79M	568.20M
	Gross Profit
363.54M	486.14M	315.94M	639.98M	580.52M	432.43M
	EBIT
72.79M	82.49M	115.75M	195.85M	121.31M	88.44M
	EBITDA
98.33M	133.40M	132.89M	235.87M	161.27M	125.09M
	Net Income Common Stockholders
60.94M	62.24M	90.15M	143.21M	84.17M	65.89M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
316.32M	343.67M	343.60M	253.13M	264.99M	203.11M
	Total Assets
1.52B	1.53B	1.53B	1.50B	1.55B	1.40B
	Total Debt
109.29M	88.17M	124.70M	96.14M	198.13M	204.89M
	Net Debt
-207.03M	-255.50M	-218.90M	-156.98M	-66.86M	1.78M
	Total Liabilities
486.82M	465.81M	484.38M	467.30M	568.67M	489.74M
	Stockholders Equity
1.02B	1.05B	1.03B	1.02B	960.79M	899.00M
Cash Flow		Free Cash Flow
74.46M	65.34M	168.79M	170.93M	107.24M	69.67M
	Operating Cash Flow
97.19M	86.25M	189.31M	196.22M	160.11M	133.15M
	Investing Cash Flow
-13.51M	-9.87M	-21.42M	-22.83M	-52.20M	-62.19M
	Financing Cash Flow
-67.81M	-76.20M	-81.55M	-183.70M	-46.87M	-20.88M

Raffles Medical Group Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.96
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:BSL, the sentiment is Neutral. The current price of 0.96 is below the 20-day moving average (MA) of 0.98, below the 50-day MA of 0.98, and above the 200-day MA of 0.90, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 34.45 is Neutral, neither overbought nor oversold. The STOCH value of 20.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SG:BSL.

Raffles Medical Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BSL	58 Neutral	$1.83B	28.96	6.02%	2.58%	6.30%	-30.93%
Sector *	53 Neutral	$5.22B	3.33	-44.36%	7.55%	16.78%	-0.12%
3H5		€749.28M	82.50	0.07%	1.03%	―	―
1B1		S$46.14M	12.24	22.81%	5.00%	―	―
40T		S$204.24M	15.99	14.45%	2.82%	―	―
5G3		S$598.63M	13.64	50.31%	4.89%	―	―
5WA		S$102.19M	40.00	-2.87%	―	―	―

Raffles Medical Group Corporate Events

Raffles Medical Group Partners with Chongqing Hospital to Enhance Medical Services

Raffles Medical Group has entered into a strategic partnership with the First Affiliated Hospital of Chongqing Municipality to enhance medical cooperation between Singapore and Chongqing. This collaboration aims to integrate international expertise with local capabilities to improve Chongqing’s medical services, providing high-quality medical resources to benefit more patients in the city.

The most recent analyst rating on (SG:BSL) stock is a Buy with a S$1.10 price target. To see the full list of analyst forecasts on Raffles Medical Group stock, see the SG:BSL Stock Forecast page.

Raffles Medical Group Holds 36th Annual General Meeting

Raffles Medical Group Ltd recently held its 36th Annual General Meeting at Suntec Singapore International Convention & Exhibition Centre. The meeting was attended by key company directors and executives, along with auditors and legal advisors. The gathering focused on reviewing the company’s performance and strategic direction, which could have implications for its market positioning and stakeholder interests.

The most recent analyst rating on (SG:BSL) stock is a Buy with a S$1.12 price target. To see the full list of analyst forecasts on Raffles Medical Group stock, see the SG:BSL Stock Forecast page.

Raffles Medical Group and Renji Hospital Launch Strategic Medical Collaboration

Raffles Medical Group and Renji Hospital have signed a strategic collaboration agreement to create a ‘dual circulation’ medical resource service system. This initiative aims to enhance collaboration between public hospitals and international medical groups, supporting Shanghai’s goal of becoming an international medical tourism hub. The partnership will integrate Raffles’ international-standard service system into domestic healthcare and promote Chinese medical expertise globally through Raffles’ network, potentially impacting the company’s operations and industry positioning.